Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Cash from Investing Activities (2023 - 2025)

Historic Cash from Investing Activities for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $15.0 million.

  • CG Oncology's Cash from Investing Activities fell 5299.17% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$159.4 million, marking a year-over-year increase of 4616.91%. This contributed to the annual value of -$300.8 million for FY2024, which is 14816.54% down from last year.
  • Latest data reveals that CG Oncology reported Cash from Investing Activities of $15.0 million as of Q3 2025, which was down 5299.17% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, CG Oncology's Cash from Investing Activities registered a high of $103.4 million during Q2 2023, and its lowest value of -$307.4 million during Q1 2024.
  • Over the past 3 years, CG Oncology's median Cash from Investing Activities value was $1.4 million (recorded in 2025), while the average stood at -$53.8 million.
  • The largest annual percentage gain for CG Oncology's Cash from Investing Activities in the last 5 years was 11983.12% (2024), contrasted with its biggest fall of 29065.81% (2024).
  • Over the past 3 years, CG Oncology's Cash from Investing Activities (Quarter) stood at $15.5 million in 2023, then fell by 29.8% to $10.9 million in 2024, then surged by 37.96% to $15.0 million in 2025.
  • Its last three reported values are $15.0 million in Q3 2025, $1.4 million for Q2 2025, and -$186.8 million during Q1 2025.